Risks and follow-up in active surveillance of prostate cancer
Expert-Guided Poster Tour 06

Location: Green Area, Room B
Chairs: A. Semjonow, Münster (DE)
       C.H. Bangma, Rotterdam (NL)
       L.H. Klotz, Toronto (CA)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

PT134

Prognostic utility of the Gleason grading system revisions


1Karolinska Institutet, Clinical Epidemiology Division, Dept. of Medicine Solna, Stockholm, Sweden,
2Sant’Orsola-Malpighi Hospital, Pathology Service, Addiari Institute of Oncology, Bologna, Italy,
3Örebro University, Dept. of Urology, Faculty of Medicine and Health, Örebro, Sweden,
4Center for Advanced Studies, Research and Development in Sardinia (CRS4), Data-Intensive Computing Division, Pula, Italy,
5University of Turin, and CPO-Piemonte, Cancer Epidemiology Unit, Dept. of Medical Sciences, Turin, Italy,
6A.O. Città della Salute e della Scienza Hospital, Dept. of Pathology, Turin, Italy,
7Karolinska Institutet and Karolinska University Hospital, Dept. of Molecular Medicine and Surgery and Dept. of Urology, Stockholm, Sweden

PT135

Association of very low PSA with increased metastases and death in patients with biopsy Gleason Score 8-10 prostate cancer


1University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany,
2University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany,
3University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany

PT136

Young age associated with increased risks of disease progression and cancer-specific mortality in prostate cancer patients


1Wan Fang Hospital Taipei Medical University, Dept. of Urology, Taipei, Taiwan,
2Taipei Medical University, Graduate Institute of Biomedical Informatics, Taipei, Taiwan,
3Taipei City Hospital, Dept. of Psychiatric Center, Taipei, Taiwan
PT137  
The effect of coffee intake and rs762551 genotype on survival following prostate cancer diagnosis

By: Gregg J.¹, Wei P.², Manyam G.², Kim J.³, Davis J.¹, Daniel C.⁴, PRACTICAL Consortium
¹UT MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ²UT MD Anderson Cancer Center, Dept. of Biostatistics, Houston, United States of America, ³Merck & Co., Clinical Research, Kenilworth, United States of America, ⁴UT MD Anderson Cancer Center, Dept. of Epidemiology, Houston, United States of America

PT138  
Initial negative multi-parametric MRI with concomitant negative biopsy: Are true negative findings confirmed over time? Results from a single institution series

By: Stabile A.¹, Fossati N.¹, Zaffuto E.¹, Gandaglia G.¹, Robesti D.¹, Cannoletta D.¹, Menean M.¹, Mazzone E.¹, Comana S.¹, Cuoci V.¹, Fallica G.¹, Cucchiara V.¹, Dell’oglio P.¹, Martini A.¹, Moschini M.², Rizzo A.¹, Mirone V.³, Necchi A.⁴, Salonia A.¹, Karakiewicz P.I.⁵, Montorsi F.¹, De Cobelli F.⁶, Briganti A.¹
¹IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy, ²Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ³University of Federico II of Naples, Dept. of Urology, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Oncology, Milan, Italy, ⁵University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, ⁶IRCCS Ospedale San Raffaele, Unit of Clinical Research in Radiology, Experimental Imaging Center, Milan, Italy

PT139  
Assessing the impact of multiparametric MRI and fusion biopsy on upgrading and upstaging during active surveillance

By: Ferriero M.C.¹, Panebianco V.², Pecoraro M.², Mastroianni R.¹, De Nunzio C.³, Bove A.M.¹, Tuderti G.¹, Anceschi U.¹, Brassetti A.¹, Guaglianone S.¹, Malossini G.⁴, Puglisi M.⁵, Gallucci M.⁶, Giuseppe S.¹
¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²Sapienza University, Dept. of Radiology, Rome, Italy, ³S. Andrea Hospital, Dept. of Urology, Rome, Italy, ⁴Rovereto Hospital, Dept. of Urology, Trento, Italy, ⁵Sapienza University, Dept. of Urology, Rome, Italy

PT140  
Upgrading according to the time between prostate biopsy and radical prostatectomy and analysis of predictive factors

¹University Hospital of Salamanca., Dept. of Urology, Salamanca, Spain, ²University Hospital of Salamanca, Dept. of Urology, Salamanca, Spain, ³University Hospital of Leon, Dept. of Urology, Leon, Spain, ⁴University Hospital of Burgos, Dept. of Urology, Burgos, Spain, ⁵Clinical Hospital of Valladolid., Dept. of Urology, Valladolid, Spain, ⁶Clinical Hospital of Valladolid, Dept. of Urology, Valladolid, Spain, ⁷Clinical Hospital of Valladolid,
The utility of micro-ultrasound in patients under active surveillance for low-risk prostate cancer: A PRIAS study extension

By: Maffei D. 1, Staerman F. 2, Paciotti M. 1, Colombo P. 3, Elefante G.M. 3, Domanico L. 1, Regis F. 1, Bevilacqua G. 1, Fasulo V. 1, Lazzi M. 1, Hurle R. 1, Saita A.R. 1, Casale P. 1, Buffi N.M. 1, Guazzoni G.F. 1, Lughezzani G. 1

1Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, 2Polyclinique de Reims-Bezannes, Dept. of Urology, Bezannes, France, 3Humanitas Clinical and Research Center, Dept. of Pathology, Rozzano, Italy

The added value of concomitant systematic biopsy in predicting biochemical recurrence after radical prostatectomy in patients with prostate cancer diagnosed by MRI-targeted biopsy

By: Gandaglia G. 1, Ploussard G. 2, Valerio M. 3, Mattei A. 4, Marra G. 5, Beauval J. 6, Malavaud B. 6, Roumigué M. 6, Marquis A. 5, Scalfi F. 1, Robesti D. 1, Rizzo A. 1, Stabile A. 1, Afferi L. 4, Moschini M. 4, Rakauskas A. 3, Van Den Bergh R. 7, De Cobelli F. 8, Fiori C. 9, Porpiglia F. 9, Gontero P. 5, Montorsi F. 1, Briganti A. 1

1IRCCS Ospedale San Raffaele, Dept. of Oncology/Unit of Urology; URI, Milan, Italy, 2Saint Jean Languedoc/La Croix du Sud Hospital, Dept. of Urology, Toulouse, France, 3Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, 4Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 5San Giovanni Battista Hospital, University of Studies of Turin, Dept. of Urology, Dept. of Surgical Sciences, Turin, Italy, 6CHU Rangueil, Dept. of Urology, Andrology and Renal Transplantation, Toulouse, France, 7St. Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, 8IRCCS Ospedale San Raffaele, Unit of Clinical Research in Radiology, Experimental Imaging Center, Milan, Italy, 9San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy

A first step towards a global nomogram to predict disease progression for men on active surveillance


1King's College London, Translational Oncology & Urology Research (TOUR), London, United Kingdom, 2Cleveland Clinic, Quantitative Health Sciences, Cleveland, United States of America, 3Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands
<table>
<thead>
<tr>
<th>PT145</th>
<th>Long-term oncological outcomes following active surveillance of low risk prostate cancer: A population-based study</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Timilshina N. 1, Finelli A. 1, Richard P. 1, Komisarenko M. 1, Martin L. 1, Tomlinson G. 2, Sander B. 2, Alibhai S. 3</td>
</tr>
<tr>
<td></td>
<td>1University Health Network, Dept. of Surgical Oncology, Toronto, Canada, 2University Health Network, Toronto Health Economics and Technology Assessment (THETA), Toronto, Canada, 3University Health Network, Dept. of Medicine, Toronto, Canada</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT146</th>
<th>Improved mortality-to-incidence ratios of prostate cancer are associated with cancer care disparities in 55 countries: Analysis of global trends from databases in 2012 and 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Sung W.W., Wang S.C., Chen S.L.</td>
</tr>
<tr>
<td></td>
<td>Chung Shan Medical University Hospital, Dept. of Urology, Taichung, Taiwan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT147</th>
<th>Usefulness of multi-parametric MRI to screen patients for active surveillance</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Song W.H., Baek S.R., Nam J.K., Sung-Woo S.W., Lee S-D.</td>
</tr>
<tr>
<td></td>
<td>Pusan National University Yangsan Hospital, Dept. of Urology, Yangsan, South Korea</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT148</th>
<th>Defining intermediate-risk prostate cancer suitable for active surveillance with PSA 10-20ng/ml: Pathological outcome analysis of a population-level dataset</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Lonergan P.E., Jeong C.W., Washington S.L., Herlemann A., Carroll P.R., Cooperberg M.R.</td>
</tr>
<tr>
<td></td>
<td>University of California, Dept. of Urology, San Francisco, United States of America</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT149</th>
<th>GG2 intermediate risk prostate cancer - population-based analysis of AS outcomes confirms worse cancer-specific and overall-survival compared to active treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Bowler N. 1, Schneider A. 1, Goldberg H. 2, Mark J.R. 3, Trabulsi E.J. 3, Lallas C.D. 3, Gomella L.G. 3, Chandrasekar T. 3</td>
</tr>
<tr>
<td></td>
<td>1Thomas Jefferson University, Sidney Kimmel Medical College, Philadelphia, United States of America, 2SUNY Upstate, Dept. of Urology, Syracuse, United States of America, 3Thomas Jefferson University, Dept. of Urology, Philadelphia, United States of America</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT150</th>
<th>Radical prostatectomy for Gleason 3+3 prostate cancer; who, how and why? Analysis of the British Association of Urological Surgeons complex operations database</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>John J.B. 1, Pascoe J. 1, Fowler S. 2, Walton T.J. 3, Johnson M.I. 4, Aning J. 5, Challacombe B.J. 6, Mcgrath J.S. 1</td>
</tr>
<tr>
<td></td>
<td>on behalf of the BAUS Section of Oncology</td>
</tr>
<tr>
<td></td>
<td>1Royal Devon and Exeter NHS Foundation Trust, Dept. of Urology, Exeter, United Kingdom</td>
</tr>
</tbody>
</table>
PT151
Risk factors which predict biopsy upgrading over time in active surveillance for prostate cancer

University of California, San Francisco, Dept. of Urology, San Francisco, CA, United States of America

PT152
Protocol adherence and outcomes among African/Afro-Caribbean men on active surveillance for prostate cancer

By: Beckmann K.1, Aya H.2, Santa Olalwa A.1, Sandu P.2, Singh S.2, Nikhil M.2, Cathcart P.2, Challacombe B.2, Poppert R.2, Dasgupta P.2, Van Hemelrijck M.1, Elhage O.2
1Kings College London, Translational Oncology and Urology Research (TOUR), London, United Kingdom, 2Guy's and St Thomas' NHS Foundation Trust, The Urology Centre, London, United Kingdom

PT153
Prostate Cancer progression in Afro-Caribbean men: Should we be using the same active surveillance protocols as Caucasian men?

By: Osinibi E., Stavrinides V., Giganti F., Moore C.M.
University College London Hospitals, Dept. of Urology, London, United Kingdom

PT154
Active surveillance for prostate cancer (CaP) in patients being activated for renal transplantation (RT)

By: Clark C.1, Chong J.C1, Kulkarni M.K1, Zakri R.Z1, Challacombe B.C2, Elhage O.E2, Brown C.B2, Dasgupta P.D2, Cathcart P.C2, Olsburgh J.O1
1Guys & St Thomas' NHS Trust, Dept. of Renal Transplant, London, United Kingdom, 2Guys & St Thomas' NHS Trust, Dept. of Urology, London, United Kingdom

PT155
Outcomes of active surveillance patients older than 75 years with early stage prostate cancer: From the PRIAS-JAPAN study

By: Takuma K.1, Sugimoto M.1, Kakehi Y.1, Matsumoto R.2, Shinohara N.2, Nakamura M.3, Kume H.3, Sasaki H.4, Egawa S.4, Hashine K.5
1Kagawa University, Dept. of Urology, kita-gun, Japan, 2Hokkaido University, Dept. of Urology, Sapporo, Japan, 3Tokyo University, Dept. of Urology, Tokyo, Japan, 4Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, 5Shikoku cancer center, Dept. of Urology, Matsuyama, Japan
<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT156</td>
<td>Physical activity decreases the risk of cancer progression in patients on active surveillance: A multicenter retrospective study</td>
<td>Brassetti A., Proietti F., Napodano G., Sanseverino R., Badenchini F., Anceschi U., Ferriero M., Mastroianni R., Tuderti G., Gallucci M., Simone G.</td>
<td>1Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 2Sapienza University, Dept. of Urology, Rome, Italy, 3Umberto I Hospital, Dept. of Urology, Nocera Inferiore, Italy, 4Istituto Nazionale Tumori, Dept. of Urology, Milan, Italy</td>
</tr>
<tr>
<td>PT157</td>
<td>Association of mediterranean diet score and disease progression among localized prostate cancer patients on active surveillance</td>
<td>Gregg J., Zhang X., Zheng J., Ward J.F., Kim J., Davis J.W., Daniel C.</td>
<td>1UT MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, 2UT MD Anderson Cancer Center, Dept. of Epidemiology, Houston, United States of America, 3Merck &amp; Co., Dept. of Clinical Research, Kenilworth, United States of America</td>
</tr>
<tr>
<td>PT158</td>
<td>Are anxiety and depression levels influenced by the choice of active surveillance or radical treatment in localized low-risk prostate cancer? The START study results</td>
<td>Porpiglia F., De Luca S., Bertetto O., Ciccone G., Rosato R., Galassi C., Bollito E., Gontero P., Garrou D., Cattaneo G., Amparore D., Checucci E., Volpi G., Manfredi M., Fiori C.</td>
<td>1AOU San Luigi Gonzaga - University of Turin, Dept. of Urology, Orbassano, Italy, 2AOU Città della Salute - Molinette San Giovanni Battista Hospital - University of Turin, Dept. of Oncology, Turin, Italy, 3CPO AOU Città della salute - University of Turin, SSD Clinical Epidemiology, Turin, Italy, 4AOU San Luigi Gonzaga - University of Turin, Dept. of Pathology, Orbassano, Italy, 5AOU Città della salute - Molinette San Giovanni Battista Hospital - University of Turin, Dept. of Urology, Turin, Italy</td>
</tr>
<tr>
<td>PT159</td>
<td>The effect of active surveillance on patient-reported erectile and urinary function. Results of the movember foundation's gap3 cohort</td>
<td>Crump T., Remmers S., Van Hemelrijck M., Helleman J., Nieboer D., Roobol M.J., Venderbos L.D.F.</td>
<td>1University of Calgary, Dept. of Surgery, Calgary, Canada, 2Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, 3King's College London, Faculty of Life Sciences and Medicine, Translational Oncology &amp; Urology Research (TOUR), London, United Kingdom</td>
</tr>
<tr>
<td>PT160</td>
<td>Trends and variations in risk stratified prostate cancer management: a cross-sectional study of the National Prostate Cancer Audit database using the Cambridge Prognostic Group criteria</td>
<td>Parry M.G., Cowling T.E., Sujenthiran A., Nossiter J., Berry B., Cathcart P., Aggarwal A., Payne H., Clarke N.W., Van Der Meulen J., Gnanapragasam V.J.</td>
<td>1London School of Hygiene and Tropical Medicine, Dept. of Health Services Research</td>
</tr>
</tbody>
</table>
and Policy, London, United Kingdom, 2The Royal College of Surgeons of England, Dept. of Clinical Effectiveness, London, United Kingdom, 3King’s College London, Dept. of Cancer Epidemiology, Dept. of Population and Global Health, London, United Kingdom, 4University College London Hospitals, Dept. of Oncology, London, United Kingdom, 5The Christie NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom, 6University of Cambridge, Dept. of Surgery, Cambridge, United Kingdom